Study of markers of systemic inflammation (matrix metalloproteinase-9, vascular endothelial adhesion molecules of type 1) in patients with ST -segment elevation myocardial infarction at the hospital and outpatient stages

Aim. To study the level of MMP-9 and VCAM-1 in patients with AMI with ST-segment elevation at the hospital stage and one year after the index event, depending on the development of complications and changes in BMI and waist size (WS).

Material and methods. The study included 126 people with STEMI after PCI, as well as 27 people in the control group. The level of MMP-9 and VCAM-1 in peripheral blood was analyzed. In addition to the standard methods of examination and diagnosis, BMI and WS were measured to identify groups with visceral obesity. The assessment of the frequency and nature of complications after STEMI was performed.

Results. The levels of biomarkers of vascular endothelial adhesion molecule type 1 and matrix metalloproteinase type 9 are increased in the acute period of STEMI, statistically significantly reduced, but remain elevated 12 months after the index event, with VCAM-1 by 3.5 times, and MMP by almost 2 times compared to the initial values. The level of MMP-9 is significantly higher in excess body mass index and waist size, and VCAM-1 has no association with visceral obesity. Vascular endothelial adhesion molecules of type 1 and matrix metalloproteinases of type 9 are increased in patients with a fatal outcome, as well as with an increase in the severity of OSN and CHF. The level of matrix metalloproteinase has a strong relationship with fatal outcome and repeated MI, and the vascular endothelial adhesion molecule type 1 has a stronger relationship with the severity of CHF.

Conclusion. The article studied markers of systemic inflammation (matrix metalloproteinase type 9 and vascular endothelial adhesion molecules type 1) in patients with ST-segment elevation myocardial infarction, depending on the presence of obesity at the hospital and outpatient stages. Simultaneous determination of MMP-9 and VCAM-1 levels can be used to assess the intensity of the inflammatory process and the risk of adverse outcomes.